MA37953A1 - Formulation de capsule composite pharmaceutique comprenant de l'irbésartan et un inhibiteur de la hmg-coa réductase - Google Patents

Formulation de capsule composite pharmaceutique comprenant de l'irbésartan et un inhibiteur de la hmg-coa réductase

Info

Publication number
MA37953A1
MA37953A1 MA37953A MA37953A MA37953A1 MA 37953 A1 MA37953 A1 MA 37953A1 MA 37953 A MA37953 A MA 37953A MA 37953 A MA37953 A MA 37953A MA 37953 A1 MA37953 A1 MA 37953A1
Authority
MA
Morocco
Prior art keywords
hmg
irbesartan
coa reductase
inhibitor
capsule formulation
Prior art date
Application number
MA37953A
Other languages
English (en)
Inventor
Yong Il Kim
Jae Hyun Park
Jong Soo Woo
Yoeng Jin Kwon
Caleb Hyungmin Park
Seung Yeop Lee
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50183919&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA37953(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of MA37953A1 publication Critical patent/MA37953A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une formulation de capsule composite pharmaceutique incluant les éléments suivants : 1) une unité d'irbésartan indépendante comprenant de l'irbésartan ou son sel pharmaceutiquement acceptable; et 2) une unité inhibitrice de la hmg-coa réductase indépendante comprenant un inhibiteur de la hmg-coa réductase ou son sel pharmaceutiquement acceptable, et un additif alcalin. Lesdites unités indépendantes sont séparées l'une de l'autre à l'intérieur d'une capsule. L'invention porte en outre sur son procédé de préparation. La formulation de capsule composite pharmaceutique, qui est conçue pour prévenir une interaction entre l'irbésartan et l'inhibiteur de la hmg-coa réductase, est améliorée en termes de stabilité et de taux de dissolution, et présente ainsi une meilleure biodisponibilité. En outre, la formulation garantit une observance médicamenteuse élevée en raison de sa petite taille, et peut ainsi être appliquée au traitement de l'hypertension et de l'hypercholestérolémie.
MA37953A 2012-08-31 2015-03-27 Formulation de capsule composite pharmaceutique comprenant de l'irbésartan et un inhibiteur de la hmg-coa réductase MA37953A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020120096036A KR20140030505A (ko) 2012-08-31 2012-08-31 이베살탄 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 약제학적 캡슐 복합제제
PCT/KR2013/007841 WO2014035190A1 (fr) 2012-08-31 2013-08-30 Formulation de capsule composite pharmaceutique comprenant de l'irbésartan et un inhibiteur de la hmg-coa réductase

Publications (1)

Publication Number Publication Date
MA37953A1 true MA37953A1 (fr) 2017-01-31

Family

ID=50183919

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37953A MA37953A1 (fr) 2012-08-31 2015-03-27 Formulation de capsule composite pharmaceutique comprenant de l'irbésartan et un inhibiteur de la hmg-coa réductase

Country Status (28)

Country Link
US (1) US20150231085A1 (fr)
EP (1) EP2890371A4 (fr)
JP (1) JP2015526509A (fr)
KR (1) KR20140030505A (fr)
CN (1) CN104602678A (fr)
AR (1) AR092385A1 (fr)
AU (1) AU2013309688A1 (fr)
BR (1) BR112015004091A2 (fr)
CA (1) CA2882738A1 (fr)
CL (1) CL2015000363A1 (fr)
CO (1) CO7350622A2 (fr)
CR (1) CR20150124A (fr)
DO (1) DOP2015000042A (fr)
EA (1) EA201590474A1 (fr)
EC (1) ECSP15010617A (fr)
IL (1) IL237425A0 (fr)
IN (1) IN2015DN01738A (fr)
MA (1) MA37953A1 (fr)
MX (1) MX2015002591A (fr)
NI (1) NI201500028A (fr)
PE (1) PE20150402A1 (fr)
PH (1) PH12015500395A1 (fr)
RU (1) RU2015111523A (fr)
SG (1) SG11201500580QA (fr)
TW (1) TW201414511A (fr)
UY (1) UY35000A (fr)
WO (1) WO2014035190A1 (fr)
ZA (1) ZA201502157B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101771766B1 (ko) * 2013-12-30 2017-08-28 알보젠코리아 주식회사 안지오텐신-Ⅱ 수용체 차단제 및 HMG-CoA 환원효소 저해제를 포함하는 약제학적 복합제제
EP3184103A1 (fr) * 2015-12-21 2017-06-28 Hexal AG Composition pharmaceutique comprenant de l'atorvastatine ou un sel de celui-ci
WO2019023198A1 (fr) * 2017-07-25 2019-01-31 Plexxikon Inc. Formulation d'un composé modulant les kinases
CN110237070A (zh) * 2019-05-10 2019-09-17 辽宁大学 厄贝沙坦在制备降血脂药物中的应用
CN116669715A (zh) * 2020-11-18 2023-08-29 Fb-Hrs有限责任公司 含有多非利特和美西律的组合物及其应用
CN113476423A (zh) * 2021-07-05 2021-10-08 海南通用三洋药业有限公司 一种瑞舒伐他汀钙胶囊的制备方法和瑞舒伐他汀钙胶囊

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI20109A (sl) * 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
PE20030324A1 (es) * 2001-07-31 2003-04-03 Warner Lambert Co Composiciones farmaceuticas de amlodipina y atorvastatina
CA2568640C (fr) * 2004-06-04 2011-08-09 Teva Pharmaceutical Industries Ltd. Composition pharmaceutique contenant de l'irbesartan
WO2008010008A2 (fr) * 2006-07-17 2008-01-24 Wockhardt Limited Combinaisons cardiovasculaires faisant appel à des inhibiteurs de rennine-angiotensine
US20110212175A1 (en) * 2006-10-30 2011-09-01 Hanall Biopharma Co., Ltd. Combination preparation comprising angiotensin-ii-receptor blocker and hmg-coa reductase inhibitor
CN101980701A (zh) * 2008-03-28 2011-02-23 菲尔若国际公司 用于预防心血管疾病的胶囊
KR20090114320A (ko) * 2008-04-29 2009-11-03 한올제약주식회사 심혈관계 질환 치료용 약제학적 제제
AU2010242938A1 (en) * 2009-04-30 2011-11-17 Dr. Reddy's Laboratories Ltd. Fixed dose drug combination formulations
KR101248804B1 (ko) * 2010-05-14 2013-03-29 한미사이언스 주식회사 ＨＭＧ-ＣｏＡ 환원효소 억제제 및 이베살탄을 포함하는 이층정 약제학적 복합제제
WO2012010977A2 (fr) * 2010-07-21 2012-01-26 Nucitec S.A. De C.V. Forme pharmaceutique quotidienne unique destinée à la prévention et au traitement du syndrome métabolique

Also Published As

Publication number Publication date
CR20150124A (es) 2015-04-24
US20150231085A1 (en) 2015-08-20
BR112015004091A2 (pt) 2017-07-04
CN104602678A (zh) 2015-05-06
AU2013309688A1 (en) 2015-02-26
ECSP15010617A (es) 2015-12-31
TW201414511A (zh) 2014-04-16
EA201590474A1 (ru) 2015-06-30
PH12015500395A1 (en) 2015-04-27
IL237425A0 (en) 2015-04-30
CO7350622A2 (es) 2015-08-10
WO2014035190A1 (fr) 2014-03-06
AR092385A1 (es) 2015-04-22
KR20140030505A (ko) 2014-03-12
ZA201502157B (en) 2016-10-26
CA2882738A1 (fr) 2014-03-06
SG11201500580QA (en) 2015-02-27
UY35000A (es) 2014-03-31
RU2015111523A (ru) 2016-10-20
IN2015DN01738A (fr) 2015-05-29
JP2015526509A (ja) 2015-09-10
CL2015000363A1 (es) 2015-06-05
MX2015002591A (es) 2015-06-10
DOP2015000042A (es) 2015-04-30
EP2890371A4 (fr) 2016-04-06
NI201500028A (es) 2017-01-04
EP2890371A1 (fr) 2015-07-08
PE20150402A1 (es) 2015-04-13

Similar Documents

Publication Publication Date Title
MA30807B1 (fr) Compositions pharmaceutiques.
MA33295B1 (fr) Nouvelle formulation de diclofénac
ATE556060T1 (de) Monocyclische anilidspirohydantoine als cgrp- rezeptorantagonisten
MY178082A (en) Solid pharmaceutical compositions and processes for their production
EA201390977A1 (ru) Комбинация агониста опиоидных рецепторов и антагониста опиоидных рецепторов для лечения болезни паркинсона
TW200733971A (en) CGRP peptide antagonists and conjugates
SG194756A1 (en) Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids
PH12013501341A1 (en) Morphinan compounds
ATE394400T1 (de) Bicyclische anilidspirohydantoine als cgrp- rezeptorantagonisten
MA37610B1 (fr) Formulations de testostérone proliposomales
WO2008131057A3 (fr) Préparations à libération contrôlée d'analgésiques opioïdes et non opioïdes
MX341482B (es) Antagonistas del receptor ep4 y su uso en el tratamiento de enfermedades mediadas por la il-23.
MA33533B1 (fr) Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles
AU2010212580A8 (en) Stable pharmaceutical composition for atherosclerosis
MA30779B1 (fr) Comprimes pediatriques de capecitabine
MA43876A (fr) Compositions pharmaceutiques et leur utilisations contre les maladies de surcharge lysosomale
MA33602B1 (fr) Composition pharmaceutique permettant de prévenir ou de traiter l'arthrite rhumatoïde, contenant du rébamipide
PH12015500395A1 (en) Pharmaceutical composite capsule formulation comprising irbesartan and hmg-coa reductase inhibitor
MA38679A1 (fr) Modulateurs du récepteur de cxcr7
UA107088C2 (xx) 5-(3,4-дихлорфеніл)-n-(2-гідроксициклогексил)-6-(2,2,2-трифторетокси)нікотинамід і його солі як засоби, що підвищують концентрацію лвщ холестерину
MA39175A1 (fr) Capsule comprend 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-(6-(4-(4-ethyl-piperazin-1-yl)-phenylamino)-pyrimidin-4-yl)-1-methyl-uree, liant et desintegrant, pour le traitement des maladies proliferatives
EA201170583A1 (ru) Новая композиция для лечения эссенциальной тромбоцитемии
IN2015DN04172A (fr)
ATE482195T1 (de) Benzoäfüisoindole als antagonisten des ep4- rezeptors
TN2012000563A1 (fr) Nouvelle association entre le 4(3-(cis-hexahydrocyclopenta(c)pyrrol-2(1-h)-yl)propoxy)benzamide et un antagoniste des recepteurs nmda et les compositions pharmaceutiques qui la contiennent.